Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations

Andrew Bodiford,1 Mahsa S Talbott,1 Nishitha M Reddy,2 1Department of Pharmacy, 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Abstract: The histone deacetylase inhibitor (HDACi), belinostat, is an emerging and novel therapeutic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bodiford A, Talbott MS, Reddy NM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Diseases of the blood and blood-forming organs
RC633-647.5
Acceso en línea:https://doaj.org/article/7f9b2bb7038a46f3b3e17cfcefd11a9f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7f9b2bb7038a46f3b3e17cfcefd11a9f
record_format dspace
spelling oai:doaj.org-article:7f9b2bb7038a46f3b3e17cfcefd11a9f2021-12-02T09:40:42ZCritical appraisal of belinostat in the management of T-cell lymphoma – patient considerations1179-9889https://doaj.org/article/7f9b2bb7038a46f3b3e17cfcefd11a9f2015-09-01T00:00:00Zhttps://www.dovepress.com/critical-appraisal-of-belinostat-in-the-management-of-t-cell-lymphoma--peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Andrew Bodiford,1 Mahsa S Talbott,1 Nishitha M Reddy,2 1Department of Pharmacy, 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Abstract: The histone deacetylase inhibitor (HDACi), belinostat, is an emerging and novel therapeutic option for patients diagnosed with relapsed/refractory peripheral T-cell lymphoma (PTCL). The PTCLs are comprised of multiple subtypes that occur in less than one per 100,000 cases in the USA. The incidence of these malignancies is rare, thus limited evidence is available. The most appropriate treatment modality has not been established. The most current recommended option is combination chemotherapy or enrollment in a clinical trial. T-cell lymphomas have emerged as a disease with marked epigenetic dysregulation. HDACi are an innovative and emerging medication class gaining increased attention in the treatment of T-cell lymphomas. There is a need to evaluate their potential place in the treatment of patients diagnosed with PTCL. Currently, the largest study evaluating belinostat use in this patient population is the BELIEF study. The BELIEF study is a single-arm, Phase II clinical trial, evaluating the use of belinostat in patients with refractory or relapsed PTCL. The primary outcome, objective response rate, was 26%, with 11% achieving a complete response and 15% a partial response. This study presents a potential novel therapeutic option in the treatment of these patients. In this paper, we review therapeutic options for PTCL and present the recent data on the role of HDACi, specifically belinostat, in the treatment of patients with relapsed/refractory PTCL. Keywords: peripheral T-cell lymphoma, novel agents, histone deacetylase inhibitorBodiford ATalbott MSReddy NMDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 109-114 (2015)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the blood and blood-forming organs
RC633-647.5
spellingShingle Diseases of the blood and blood-forming organs
RC633-647.5
Bodiford A
Talbott MS
Reddy NM
Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
description Andrew Bodiford,1 Mahsa S Talbott,1 Nishitha M Reddy,2 1Department of Pharmacy, 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Abstract: The histone deacetylase inhibitor (HDACi), belinostat, is an emerging and novel therapeutic option for patients diagnosed with relapsed/refractory peripheral T-cell lymphoma (PTCL). The PTCLs are comprised of multiple subtypes that occur in less than one per 100,000 cases in the USA. The incidence of these malignancies is rare, thus limited evidence is available. The most appropriate treatment modality has not been established. The most current recommended option is combination chemotherapy or enrollment in a clinical trial. T-cell lymphomas have emerged as a disease with marked epigenetic dysregulation. HDACi are an innovative and emerging medication class gaining increased attention in the treatment of T-cell lymphomas. There is a need to evaluate their potential place in the treatment of patients diagnosed with PTCL. Currently, the largest study evaluating belinostat use in this patient population is the BELIEF study. The BELIEF study is a single-arm, Phase II clinical trial, evaluating the use of belinostat in patients with refractory or relapsed PTCL. The primary outcome, objective response rate, was 26%, with 11% achieving a complete response and 15% a partial response. This study presents a potential novel therapeutic option in the treatment of these patients. In this paper, we review therapeutic options for PTCL and present the recent data on the role of HDACi, specifically belinostat, in the treatment of patients with relapsed/refractory PTCL. Keywords: peripheral T-cell lymphoma, novel agents, histone deacetylase inhibitor
format article
author Bodiford A
Talbott MS
Reddy NM
author_facet Bodiford A
Talbott MS
Reddy NM
author_sort Bodiford A
title Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
title_short Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
title_full Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
title_fullStr Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
title_full_unstemmed Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
title_sort critical appraisal of belinostat in the management of t-cell lymphoma – patient considerations
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/7f9b2bb7038a46f3b3e17cfcefd11a9f
work_keys_str_mv AT bodiforda criticalappraisalofbelinostatinthemanagementoftcelllymphomandashpatientconsiderations
AT talbottms criticalappraisalofbelinostatinthemanagementoftcelllymphomandashpatientconsiderations
AT reddynm criticalappraisalofbelinostatinthemanagementoftcelllymphomandashpatientconsiderations
_version_ 1718398073445548032

Ejemplares similares